6-benzyloxycarbonylaminocapronoyl chloride | 4644-75-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-benzyloxycarbonylaminocapronoyl chloride
• 英文别名: N-CBZ-6-aminohexanoic acid chloride；(5-chlorocarbonyl-pentyl)-carbamic acid benzyl ester；Benzyl (6-chloro-6-oxohexyl)carbamate；benzyl N-(6-chloro-6-oxohexyl)carbamate
• CAS: 4644-75-1
• 化学式: C₁₄H₁₈ClNO₃
• 分子量: 283.755
• InChiKey: SPHAWGSPLGYKBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  6-benzyloxycarbonylaminocapronoyl chloride 在 sodium hydroxide 、 乙醇 、 氯仿 、 镍 作用下， 生成 6-(6-氨基己酰氨基)己酸
  参考文献：
  名称：

  West, Faserforschung und Textiltechnik, 1954, vol. 5, p. 145,153

  摘要：

  DOI：
• 作为产物：
  描述：

  6-氨基己酸 在 草酰氯 作用下， 以 sodium hydroxide 、 乙醚 、 二氯甲烷 为溶剂， 生成 6-benzyloxycarbonylaminocapronoyl chloride
  参考文献：
  名称：

  Supramolecular hydrogel formed by glucoheptonamide of l-lysine: simple preparation and excellent hydrogelation ability

  摘要：

  We describe the simple preparation of new L-lysine derivatives with a gluconic or glucoheptonic group, their hydrogelation properties, and the thermal and mechanical properties of the supramolecular hydrogels. The L-lysine derivatives with a gluconic group have no hydrogelation ability, while the L-lysine-glucoheptonamide derivatives functioned as hydrogelators. Their hydrogelation abilities increased with the decreasing length of the spacer between the L-lysine segment and the glucoheptonic group. The compound, which has no spacer, formed a supramolecular hydrogel at 0.05 wt% in pure water. The thermal stability and high mechanical strength of the supramolecular hydrogels based on this compound significantly depended on the aqueous solutions. Electron microscopy and FTIR studies demonstrated that the hydrogelators created a three-dimensional network through hydrogen bonding and hydrophobic interactions in the supramolecular hydrogel. In addition, it was found that hydrophobic interactions played an important role in the thermal stability of the supramolecular hydrogel. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2007.02.065
• 作为试剂：
  描述：

  泊马度胺 、 乙酸乙酯 在 6-benzyloxycarbonylaminocapronoyl chloride 、 四氢呋喃 、 ethyl acetate n-hexane 作用下， 反应 4.0h， 以to give 1.24 g (48%) of product as an off-white solid的产率得到{5-[2-(2,6-Dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylcarbamoyl]-pentyl}-carbamic acid benzyl ester
  参考文献：
  名称：

  Isoindole-imide compounds, compositions, and uses thereof

  摘要：

  本发明涉及isoindole-imide化合物及其药学上可接受的盐、水合物、溶剂合物、笼合物、对映体、非对映异构体、外消旋体或其立体异构体混合物，包括这些isoindole-imide化合物的药物组成物，以及降低哺乳动物中细胞因子及其前体水平的方法。特别是，本发明涉及对哺乳动物中TNF-α的产生具有强效抑制作用的isoindole-imide化合物。本文所描述的isoindole-imide化合物可用于治疗或预防哺乳动物中的疾病或障碍，例如，癌症，如实体瘤和血液性肿瘤；心脏病，例如充血性心力衰竭；骨质疏松症；以及遗传性、炎症性、过敏性和自身免疫性疾病。

  公开号：

  US07576104B2

文献信息

• SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS
  申请人：LIFE TECHNOLOGIES CORPORATION

  公开号：US20160025713A1

  公开（公告）日：2016-01-28

  The present invention provides methods and fluorescent compounds that facilitate detecting and labeling of a fusion protein by being capable of selectively binding to an affinity tag. The fluorescent compounds have the general formula A(B)n, wherein A is a fluorophore, B is a binding domain that is a charged chemical moiety, a protein or fragment thereof and n is an integer from 1-6 with the proviso that the protein or fragment thereof not be an antibody or generated from an antibody. The present invention provides specific fluorescent compounds and methods used to detect and label fusion proteins that contain a poly-histidine affinity tag. These compounds have the general formula A(L)m(B)n wherein A is a fluorophore, L is a linker, B is an acetic acid binding domain, m is an integer from 1 to 4 and n is an integer from 1 to 6. The acetic acid groups interact directly with the positively charged histidine residues of the affinity tag to effectively label and detect a fusion protein containing such an affinity tag when present in an acidic or neutral environment.

  本发明提供了一种方法和荧光化合物，通过选择性地与亲和标签结合，从而促进融合蛋白的检测和标记。所述荧光化合物具有通式A(B)n，其中A是荧光团，B是带电化学基团、蛋白质或其片段的绑定域，n是1-6的整数，但该蛋白质或其片段不是抗体或由抗体产生的。本发明还提供了特定的荧光化合物和方法，用于检测和标记含有聚组氨酸亲和标签的融合蛋白。这些化合物具有通式A(L)m(B)n，其中A是荧光团，L是连接器，B是醋酸绑定域，m是1到4的整数，n是1到6的整数。醋酸基团直接与亲和标签中的正电荷组氨酸残基相互作用，有效地标记和检测含有此类亲和标签的融合蛋白，当其存在于酸性或中性环境中时。
• Development of Active Center-Directed Inhibitors against Plasmin.
  作者：Naoki TENO、Keiko WANAKA、Yoshio OKADA、Yuko TSUDA、Utako OKAMOTO、Akiko HIJIKATA-OKUNOMIYA、Taketoshi NAITO、Shosuke OKAMOTO

  DOI：10.1248/cpb.39.2340

  日期：——

  Active center-directed inhibitors of plasmin were designed based on the structure of specific substrates of plasmin and then synthesized. Their effects on plasmin were examined and the structure-inhibitory activity relationship was studied. Nα-trans-4-Aminomethylcyclohexanecarbonyllysine 4-benzoylanilide (Tra-Lys-BZA) inhibited plasmin activities toward S-2251 and fibrin with IC50 values of 15 and 6.1 μM, respectively and Nα-trans-4-aminomethylcyclohexanecarbonyllysine 4-benzylpiperidine amide (Tra-Lys-BPP) did not show any detectable inhibitory activity. Moreover, it was revealed that Tra-Lys-4-methoxycarbonylanilide inhibited plasma kallikrein more potently than plasmin.

  基于纤溶酶的特定底物结构设计了活性中心导向的纤溶酶抑制剂，并进行了合成。研究了它们对纤溶酶的效应以及结构-抑制活性的关系。Nα-反式-4-氨甲基环己烷羰基赖氨酸4-苯甲酰苯胺（Tra-Lys-BZA）对S-2251和纤维蛋白的IC50值分别为15和6.1μM，而Nα-反式-4-氨甲基环己烷羰基赖氨酸4-苄基哌啶酰胺（Tra-Lys-BPP）则没有显示出任何可检测的抑制活性。此外，研究发现Tra-Lys-4-甲氧羰基苯胺对血浆激肽释放酶的抑制作用比纤溶酶更强。
• Compositions and methods for detection and isolation of phosphorylated molecules
  申请人：Molecular Probes, Inc.

  公开号：US07102005B2

  公开（公告）日：2006-09-05

  The present invention relates to phosphate-binding compounds that find use in binding, detecting and isolating phosphorylated target molecules including the subsequent identification of target molecules that interact with phosphorylated target molecules or molecules capable of being phosphorylated. A binding solution is provide that comprises a phosphate-binding compound, an acid and a metal ion wherein the metal ion simultaneously interacts with an exposed phosphate group on a target molecule and the metal chelating moiety of the phosphate-binding compound forming a bridge between the phosphate-binding compound and a phosphorylated target molecule resulting in a ternary complex. The binding solution of the present invention finds use in binding and detecting immobilized and solubilized phosphorylated target molecules, isolation of phosphorylated target molecules from a complex mixture and aiding in proteomic analysis wherein kinase and phosphatase substrates and enzymes can be identified.

  本发明涉及磷酸结合化合物，用于结合、检测和分离包括随后鉴定与磷酸化靶分子相互作用或能够被磷酸化的分子的靶分子。提供一种包含磷酸结合化合物、酸和金属离子的结合溶液，其中金属离子同时与靶分子上的暴露的磷酸基团以及磷酸结合化合物的金属螯合基团相互作用，形成将磷酸结合化合物与磷酸化靶分子之间形成桥梁的三元复合物。本发明的结合溶液用于结合和检测固定和溶解的磷酸化靶分子，从复杂混合物中分离磷酸化的靶分子，并有助于蛋白质组学分析，其中激酶和磷酸酶底物和酶可被鉴定。
• Quinazolinone derivatives
  申请人：——

  公开号：US20040077667A1

  公开（公告）日：2004-04-22

  A quinazolinone derivatives having poly (adenosine 5′-diphaspho-ribose)polymerase (PARP) inhibotory activity represented by the formula (I), wherein R1 is optionally substituted cyclic amino groups or optionally substituted amino group, R2 is substituent, n means an integer from 0 to 4, and L is lower akkylene or lower alkenylene, or its prodrug, or their salts. 1

  一种具有聚(腺苷酸二磷酸核糖)聚合酶（PARP）抑制活性的喹唑啉酮衍生物，其化学式为（I），其中R1是可选取代的环氨基或可选取代的氨基基团，R2是取代基，n表示0至4的整数，L是低级别的取代基或低级别的烯基取代基，或其前药或盐。
• [EN] ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF<br/>[FR] COMPOSES ISOINDOLE-IMIDES UTILISES EN TANT QU'INHIBITEURS DU TNF
  申请人：CELGENE CORP

  公开号：WO2002059106A1

  公开（公告）日：2002-08-01

  The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potents inhibitors of the production of the TNF-α in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory, allergic; and autoimmune diseases.

  本发明涉及异吲哚酰亚胺化合物及其药学上可接受的盐、水合物、溶剂物、笼合物、对映体、非对映体、外消旋体或其立体异构体混合物，以及包含这些异吲哚酰亚胺化合物的制药组合物，以及在哺乳动物中降低细胞因子及其前体水平的方法。具体而言，本发明涉及异吲哚酰亚胺化合物，其是哺乳动物中TNF-α产生的有效抑制剂。本文所描述的异吲哚酰亚胺化合物可用于治疗或预防哺乳动物的疾病或障碍，例如癌症，如实体肿瘤和血液性肿瘤；心脏病，如充血性心力衰竭；骨质疏松症；以及遗传性、炎症性、过敏性和自身免疫性疾病。